Sihuan Pharmaceutical Announces 2014 Interim Results Profit Attributable to Owners of the Company Up by 34.4% Leveraging Diversified Product...
Sihuan Pharmaceutical Announces 2013 Annual Results Revenue and Profit Attributable to Owners of the Company Up by 55.6% and 44.1...
CFDA Accepts Sihuan Pharmaceutical's Application for Clinical Trial Approval for Self-Developed Innovative Oncology Drug Pirotinib To further...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.